Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K8NW
|
|||
| Former ID |
DNC001217
|
|||
| Drug Name |
Ritanserin
|
|||
| Synonyms |
ritanserin; 87051-43-2; Tiserton; Ritanserine; Ritanserinum; Ritanserina; R-55667; Ritanserinum [Latin]; Ritanserine [French]; Ritanserina [Spanish]; UNII-145TFV465S; C27H25F2N3OS; R 55,667; 6-(2-(4-(bis(4-fluorophenyl)methylene)piperidin-1-yl)ethyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; MLS000069360; CHEMBL267777; 6-(2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl)-7-methyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one; N,N-dialkyl-dipeptidylamines
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Discontinued in Phase 3 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H25F2N3OS
|
|||
| Canonical SMILES |
CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3
|
|||
| InChI |
1S/C27H25F2N3OS/c1-18-24(26(33)32-16-17-34-27(32)30-18)12-15-31-13-10-21(11-14-31)25(19-2-6-22(28)7-3-19)20-4-8-23(29)9-5-20/h2-9,16-17H,10-15H2,1H3
|
|||
| InChIKey |
JUQLTPCYUFPYKE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 87051-43-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
855736, 7379883, 8149992, 8153123, 11111716, 11335367, 11360606, 11364744, 11367306, 11369868, 11372124, 11378033, 11461578, 11485176, 11489376, 11490838, 11495644, 12013534, 14834621, 17405639, 24278117, 26680887, 29224143, 47207399, 47216659, 47885282, 47959597, 48334360, 50057747, 50100336, 50104035, 50104036, 50104037, 50123110, 53301609, 53778189, 53788831, 56311639, 56423112, 57322596, 85089208, 85209702, 85231205, 85789270, 90340705, 91011597, 92303281, 92307929, 99301280, 103025197
|
|||
| ChEBI ID |
CHEBI:64195
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 97). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000237) | |||
| REF 3 | Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat. Eur J Pharmacol. 2008 Sep 11;592(1-3):133-7. | |||
| REF 4 | Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-tre... J Psychiatr Res. 2008 Sep;42(11):894-901. | |||
| REF 5 | Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. Behav Pharmacol. 2008 Mar;19(2):145-52. | |||
| REF 6 | Combined treatment of portal hypertension with ritanserin and propranolol in conscious and unrestrained cirrhotic rats. Hepatology. 1992 May;15(5):878-82. | |||
| REF 7 | Human embryonic stem cell-derived oligodendrocyte progenitor cells express the serotonin receptor and are susceptible to JC virus infection. J Virol. 2008 Sep;82(17):8896-9. | |||
| REF 8 | p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol. 1998 Oct 23;359(2-3):185-90. | |||
| REF 9 | N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.